TREML1/TLT-1 Antibody [Alexa Fluor® 532]

• Reactivity: Mu
• Applications: WB
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Alexa Fluor 532

TREML1/TLT-1 Antibody [Alexa Fluor® 532] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse TREML1/TLT‑1
  Gly18-Cys178
  Accession # NP_082039
• Specificity: Detects mouse TREML1/TLT‑1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 10% cross-reactivity with recombinant human TREML1 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TREML1/TLT-1 Antibody [Alexa Fluor® 532]

• dJ238O23.3
• GLTL1825
• PRO3438
• TLT1
• TLT-1
• TLT1MGC119173
• TREML1
• trem-like transcript 1 protein
• triggering receptor expressed on myeloid cells-like 1
• Triggering receptor expressed on myeloid cells-like protein 1

Background

Triggering receptor expressed on myeloid cells-like protein 1 (TREML1)/TREM-like transcript-1 (TLT‑1) is a 40 kDa type I transmembrane receptor and member of the TREM family of proteins (1). Mouse TREML1/TLT-1 is synthesized as a 317 amino acid (aa) precursor that contains a 20 aa signal sequence, a 155 aa extracellular domain (ECD), a 21 aa transmembrane region, and a 121 aa cytoplasmic domain (SwissProt #: Q8K558). The ECD contains an Ig-like V-type domain (aa 21‑122), and the cytoplasmic region contains a proline-rich region (aa 245‑275) and an immunoreceptor tyrosine-based inhibition motif (ITIM) characterized by the residues S/I/V/LXYXXV/L (1). A splicing variant produces a second isoform that has a six aa substitution for aa 173 in isoform 1. Mature mouse TREML1/TLT-1 shares 65% aa sequence identity with mature human TREML1/TLT-1. TREML1/TLT-1 is expressed exclusively in megakaryocytes and platelets where it colocalizes with CD62P in alpha ‑granules in resting platelets and on the cell surface of platelets activated by thrombin (1‑3). The receptor’s expression is up‑regulated dramatically upon platelet activation (2). Antibodies to single-chain Fv fragments specific for TLT-1 inhibited thrombin-mediated human platelet aggregation suggesting its role in the regulation of aggregation (5). In addition, soluble fragments including the ECD can be released into serum by proteolysis (3). The phosphorylated TREML1/TLT-1 is able to interact with both SHP-1 and SHP-2 through ITIM (1, 4). SHP-2 interaction enhances Fc epsilon RI-mediated calcium signaling in rat basophilic leukemia cells (1). It is hypothesized that TREML1/TLT-1 plays a role in the innate and adaptive immune responses.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • NP_082039()